Randomized Double-Blind Placebo-Controlled Trial of Desmopressin for Post-Kidney Biopsy Bleeding.

ABSTRACT:

Introduction

This study evaluated the efficacy and safety of desmopressin in reducing postbiopsy bleeding in patients undergoing kidney biopsy, a common complication requiring effective prevention strategies.

Methods

In this double-blind, randomized, placebo-controlled trial conducted from February 2019 to January 2023 at a teaching institute in Lucknow, India, 203 patients aged 18 to 65 years undergoing indication kidney biopsy were randomized to receive desmopressin (300 μg) or placebo intranasally an hour before the procedure. Outcomes included postbiopsy bleeding (primary) and hemoglobin drop, hypotension, hematuria, hematoma, transfusion need, and radiological or surgical interventions (secondary).

Results

Bleeding incidence was significantly lower in the desmopr

SUBMITTER: Prasad N 

PROVIDER: S-EPMC12266218 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature